Status:
COMPLETED
A Study of LY3502970 in Healthy Male Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
MALE
35-55 years
Phase:
PHASE1
Brief Summary
The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to eliminate it. This study will involve a single dose of ¹⁴C radiolabe...
Eligibility Criteria
Inclusion
- Are overtly healthy males
- Body weight within 50 and 100 kilograms (kg), inclusive, and body mass index within the range 18.0 and 32.0 kilograms per square meter (kg/m²) (inclusive)
Exclusion
- Females
- Have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product (IP); or of interfering with the interpretation of data
- Have a history of Gilbert's syndrome or have total bilirubin level (TBL) above upper limit of normal (ULN) at screening
- Have evidence of significant active neuropsychiatric disease, as determined by the investigator
- Have had any exposure to LY3502970 or any other glucagon-like peptide-1 (GLP-1) analogs, or other related compounds within the prior 3 months, or any history of allergies to these medications
- Are currently enrolled in a clinical study involving an investigational product (IP) or any other type of medical research judged not to be scientifically or medically compatible with this study
- Have participated, within the last 3 months, in a clinical study involving an IP. If the previous IP has a long half-life, 5 half-lives or 3 months (whichever is longer) should have passed, prior to check-in
- Have participated in any clinical trial involving a radiolabeled IP within 12 months prior to check-in
- Show evidence of human immunodeficiency virus (HIV) infection and/or positive HIV antibodies
- Show evidence of hepatitis C and/or positive hepatitis C antibody
- Show evidence of hepatitis B and/or positive hepatitis B surface antigen
- Have had exposure to significant diagnostic, therapeutic, or employment-related radiation within 12 months prior to dosing (e.g., serial x-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring)
Key Trial Info
Start Date :
March 29 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 3 2021
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT04680767
Start Date
March 29 2021
End Date
July 3 2021
Last Update
July 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Covance Clinical Research
Leeds, United Kingdom, LS2 9LH